EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2674-2683

  Winkler, Johannes ^a,c   Martin Killias, Patricia ^b   Plückthun, Andreas ^b   Zangemeister Wittke, Uwe ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; LIPOFECTAMINE; MESSENGER RNA; NUCLEIC ACID; PROTAMINE; PROTEIN BCL 2; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DENATURATION; DOWN REGULATION; EMBRYO; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; INTERNALIZATION; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; RNA INTERFERENCE;

ANKYRIN REPEAT; ANTIGENS, NEOPLASM; BASE SEQUENCE; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; MICROSCOPY, CONFOCAL; NANOTECHNOLOGY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 70349512496     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0402     Document Type: Article

References (41)

1. Wilkinson A. Oligonucleotide therapeutics: the next big thing. Scrip Executive Briefing 2008;1:1-12.
2. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-330 (Pubitemid 38295766)
3. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007;117:3615-3622
4. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008;19:125-132 (Pubitemid 351278372)
5. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucl Acids Res 2008;36:4158-4171 (Pubitemid 351984831)
6. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: An update on delivery. Curr Opin Mol Ther 2008;10:158-167
7. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178 (Pubitemid 39545841)
8. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717 (Pubitemid 41716361)
9. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 2007;104:4095-4100 (Pubitemid 47181584)
10. Mayer G, Vogel V, Weyermann J, et al. Oligonucleotide-protamine-albumin nanoparticles: protamine sulfate causes drastic size reduction. J Control Release 2005;106:181-187 (Pubitemid 41140093)
11. Medberry P, Dennis S, Van Hecke T, DeLong RK. pDNA bioparticles: comparative heterogeneity, surface, binding, and activity analyses. Biochem Biophys Res Commun 2004;319:426-432 (Pubitemid 38725964)
12. Vogel V, Lochmann D, Weyermann J, et al. Oligonucleotide-protamine- albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release 2005;103:99-111. (Pubitemid 40248565)
13. Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-135 (Pubitemid 43088552)
14. Spizzo G, Gastl G, Obrist P, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-213 (Pubitemid 39070963)
15. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110 (Pubitemid 46067310)
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988 (Pubitemid 36418143)
17. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115 (Pubitemid 46067311)
18. Trzpis M, McLaughlin PMJ, de Leij LMFH, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171:386-395 (Pubitemid 47344671)
19. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-171
20. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003;9:2837-2848 (Pubitemid 36842130)
21. Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 2006;5:3170-3180 (Pubitemid 46092060)
22. Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007;6:3019-3027 (Pubitemid 350206780)
23. Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotech 2004;22:575-582 (Pubitemid 38590636)
24. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332:489-503. (Pubitemid 37020959)
25. Zahnd C, Wyler E, Schwenk JM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007;369:1015-1028 (Pubitemid 46754059)
26. Zahnd C, Pecorari F, Straumann N, Wyler E, Plückthun A. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 2006;281:35167-35175 (Pubitemid 46036556)
27. Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A 1997;94:4937-4942
28. Zahnd C, Amstutz P, Plückthun A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Meth 2007;4:269-279 (Pubitemid 46358879)
29. Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105. (Pubitemid 27356788)
30. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-1733 (Pubitemid 30948874)
31. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-479
32. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000.
33. Wetzel SK, Settanni G, Kenig M, Binz HK, Plückthun A. Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol 2008;376:241-257
34. Li W, Szoka F. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007;24:438-449 (Pubitemid 46295166)
35. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Plückthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185HER-2 miniantibodies multimerized by self-associating peptides. J Biol Chem 2001;276:14385-14392 (Pubitemid 37391829)
36. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006;281:35186-35201 (Pubitemid 46043248)
37. Noe CR, Winkler J, Urban E, Gilbert M, Haberhauer G, Brunar H. Zwitterionic oligonucleotides: a study on binding properties of 2′-O-aminohexyl modifications. Nucleosides Nucleotides Nucleic Acids 2005;24:1167-1185 (Pubitemid 43154761)
38. Sioud M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci 2008;13:4379-4392
39. Winkler J, Gilbert M, Kocourková A, Stessl M, Noe CR. 2′-O-lysylaminohexyl oligonucleotides: modifications for antisense and siRNA. ChemMedChem 2008;3:102-110
40. Stessl M, Marchetti-Deschmann M, Winkler J, Lachmann B, Allmaier G, Noe CR. A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. J Proteomics 2009;72:1019-1030
41. Winkler J, Saadat K, Díaz-Gavilán M, Urban E, Noe CR. Oligonucleotide polyamine conjugates: Influence of length and position of 2′-attached polyamines on duplex stability and antisense effect. Eur J Med Chem 2009;44:670-677